Karolina Krystyna Kopeć

Ms. Karolina Krystyna Kopeć

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FCFederico Cannas
Federico Cannas
KKKarolina Krystyna Kopeć
Karolina Krystyna Kopeć
NZNatalia Zuddas
Natalia Zuddas
FLAMINIA CESARE MARINCOLAFLAMINIA CESARE MARINCOLA
FLAMINIA CESARE MARINCOLA
GAGiorgio Arcara
Giorgio Arcara
Vassilios FanosVassilios Fanos
Vassilios Fanos
Background: Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder characterized by motor and non-motor symptoms. As conventional diagnostic methods are limited in their ability to detect early-stage PD or monitor its progression, there is growing interest in identifying molecular biomarkers with clinical utility. This systematic review synthesizes recent advancements in the application of metabolomics to PD, with a specific focus on human studies published between 2019 and 2024, a period of notable growth in the research area. Methods: Following PRISMA 2020 guidelines, a comprehensive literature search was conducted across major scientific databases. After screening, 16 eligible original studies were selected based on predefined criteria. Key features extracted included study design, biofluid type, analytical platform, statistical approach, and main findings. Results: Consistent metabolic alterations were observed across several biological pathways, including amino acid metabolism, lipid regulation, mitochondrial energy production, oxidative stress, polyamine metabolism, as well as in gut microbiota-derived metabolites. Biofluids analyzed included plasma, serum, cerebrospinal fluid, saliva, urine, and sebum. While plasma and serum remained the most studied matrices, emerging interest in non-invasive fluids such as saliva and sebum reflects their potential in clinical settings. Methodological heterogeneity was noted across studies, particularly in confounder adjustment and study design. Conclusions: Despite certain limitations, the included studies collectively point to the potential of metabolomics in identifying robust diagnostic and prognostic signatures for PD. This review emphasizes the need for longitudinal studies, methodological standardization, and integration with other omics approaches to advance biomarker discovery and support the development of precision medicine strategies for PD.

10 February 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
KKKarolina Krystyna Kopeć
Karolina Krystyna Kopeć
GUGabrieleanselmo Uccheddu
Gabrieleanselmo Uccheddu
PCPaweł Chodnicki
Paweł Chodnicki
Antonio NotoAntonio Noto
Antonio Noto
CPCristina Piras
Cristina Piras
Vassilios FanosVassilios Fanos
Vassilios Fanos
Osteoarthritis (OA) and rheumatoid arthritis (RA) are joint diseases that share similar clinical features but have different etiologies, making a differential diagnosis particularly challenging. Background/Objectives: Utilizing advanced machine learning (ML) techniques on metabolomic data, this study aimed to identify key metabolites in synovial fluid (SF) that could aid in distinguishing between OA and RA. Methods: Metabolite data from the MetaboLights database (MTBLS564), analyzed using nuclear magnetic resonance (NMR), were processed using normalization, a principal component analysis (PCA), and a partial least squares discriminant analysis (PLS-DA) to reveal prominent clustering. Results: Decision forests and random forest classifiers, optimized using genetic algorithms (GAs), highlighted a selection of a few metabolites—primarily glutamine, pyruvate, and proline—with significant discriminative power. A Shapley additive explanations (SHAP) analysis confirmed these metabolites to be pivotal predictors, offering a streamlined approach for clinical diagnostics. Conclusions: Our findings suggest that a minimal set of key metabolites can effectively be relied upon to distinguish between OA and RA, supported by an optimized ML model achieving high accuracy. This workflow could streamline diagnostic efficiency and enhance clinical decision-making in rheumatology.

12 November 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MPMonica Pibiri
Monica Pibiri
Antonio NotoAntonio Noto
Antonio Noto
ADAntonio Dalu
Antonio Dalu
SMSandro Muntoni
Sandro Muntoni
KKKarolina Krystyna Kopeć
Karolina Krystyna Kopeć
CPCristina Piras
Cristina Piras
Background: High-throughput metabolomics studies have promoted the discovery of candidate biomarkers linked to atherosclerosis (AS). This narrative systematic review summarises metabolomics studies conducted in (1) individuals with subclinical AS (assessed by imaging techniques such as carotid intimal media thickness, IMT, and coronary artery calcium, CAC), (2) patients with established atherosclerotic plaques, and (3) individuals with AS risk factors. Methods: The systematic search was conducted in the PubMed database according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. The inclusion criteria were as follows: (i) publication date between 2009 and 2024; (ii) identification of potential biomarkers for AS in subjects with a diagnosis of AS or with one or more traits characteristic of the disease (i.e., CAC or IMT); (iii) identification of potential AS biomarkers in subjects with atherogenic clinical conditions (i.e., Down’s syndrome, DS, polycystic ovarian syndrome, PCOS, and systemic lupus erythematosus, SLE); (iv) metabolomic studies; and (iv) studies in human samples. Exclusion criteria comprised the following: (i) studies on lipid metabolic diseases unrelated to AS, (ii) “omics” results not derived from metabolomics, (iii) reviews and studies in animal models or cell cultures, and (iv) systematic reviews and meta-analyses. Of 90 eligible studies screened, 24 met the inclusion criteria. Results: Across subclinical and overt AS, consistent disturbances were observed in amino acid, lipid, and carbohydrate metabolism. Altered profiles included branched-chain amino acids (BCAAs), aromatic amino acids (AACs) and derivatives (e.g., kynurenine–tryptophan pathway), bile acids (BAs), androgenic steroids, short-chain fatty acids (FAs)/ketone intermediates (e.g., acetate, 3-hydroxybutyrate, 3-HB), and Krebs cycle intermediates (e.g., citrate). Several metabolites (e.g., glutamine, lactate, 3-HB, phosphatidylcholines, PCs/lysophosphatidylcholines, lyso-PCs) showed reproducible associations with vascular phenotypes (IMT/CAC) and/or clinical AS. Conclusions: The identification of low-weight metabolites altered in both subclinical and overt AS suggests their potential as candidate biomarkers for early AS diagnosis. Given the steady increase in deaths from cardiovascular disease, a manifestation of advanced AS, this finding could have significant clinical relevance.

15 August 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
Hema Sekhar Reddy RajulaHema Sekhar Reddy Rajula
Hema Sekhar Reddy Rajula
CPCristina Piras
Cristina Piras
KKKarolina Krystyna Kopeć
Karolina Krystyna Kopeć
Antonio NotoAntonio Noto
Antonio Noto
MSMartina Spada
Martina Spada
Vassilios FanosVassilios Fanos
Vassilios Fanos
Background: This study investigates metabolic perturbations in serum samples associated with different genotypes (AA, AC, and CC) of the schizophrenia susceptibility gene NOS1AP-rs12742393. Methods: Publicly available datasets acquired using ultra-performance liquid chromatography–quadrupole time-of-flight mass spectrometry (UPLC–QTOFMS) were analyzed by employing network and enrichment approaches. Results: Key metabolites, including tryptophan, 2-aminobutyric acid, palmitic acid, and 5-hydroxytryptophan, were strongly linked to metabolic networks in genotypes AA-AC and AA. Enrichment analysis was conducted to identify metabolite sets differentially distributed across these genotypes, with a particular focus on genotype AA. Conclusions: The findings suggest that NOS1AP-rs12742393 contributes to complex metabolic alterations involving amino acids, organic compounds, fatty acids, and cholic acids. Moreover, serum metabolome analysis demonstrates sufficient sensitivity and specificity to provide insights into NOS1AP-rs12742393 genotype-associated metabolic profiles, supporting a network-based approach to understanding schizophrenia susceptibility.